Multiplex assay for comprehensive genotyping of genes involved in drug metabolism, excretion, and transport.

BACKGROUND Drug metabolism is a multistep process by which the body disposes of xenobiotic agents such as therapeutic drugs. Genetic variation in the enzymes involved in this process can lead to variability in a patient's response to medication. METHODS We used molecular-inversion probe technology to develop a multiplex genotyping assay that can simultaneously test for 1227 genetic variants in 169 genes involved in drug metabolism, excretion, and transport. Within this larger set of variants, we performed analytical validation of a clinically defined core set of 165 variants in 27 genes to assess accuracy, imprecision, and dynamic range. RESULTS In a test set of 91 samples, genotyping accuracy for the core set probes was 99.8% for called genotypes, with a 1.2% no-call (NC) rate. The majority of the core set probes (133 of 165) had < or = 1 genotyping failure in the test set; a subset of 12 probes was responsible for the majority of failures (mainly NC). Genotyping results were reproducible upon repeat testing with overall within- and between-run variation of 1.1% and 1.4%, respectively-again, primarily NCs in a subset of probes. The assay showed stable genotyping results over a 6-fold range of input DNA. CONCLUSIONS This assay generates a comprehensive assessment of a patient's metabolic genotype and is a tool that can provide a more thorough understanding of patient-to-patient variability in pharmacokinetic responses to drugs.

[1]  J. de Leon,et al.  A Poor Metabolizer for Cytochromes P450 2D6 and 2C19: A Case Report on Antidepressant Treatment , 2006, CNS Spectrums.

[2]  H. Ueoka,et al.  Polymorphisms of UDP-Glucuronosyltransferase and Pharmacokinetics of Irinotecan , 2002, Therapeutic drug monitoring.

[3]  Fuli Yu,et al.  Highly multiplexed molecular inversion probe genotyping: over 10,000 targeted SNPs genotyped in a single tube assay. , 2005, Genome research.

[4]  P. O'dwyer,et al.  Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  P. Wedlund The CYP2C19 Enzyme Polymorphism , 2000, Pharmacology.

[6]  M. Ingelman-Sundberg,et al.  Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. , 1995, The Journal of pharmacology and experimental therapeutics.

[7]  Howard L McLeod,et al.  Pharmacogenomics--drug disposition, drug targets, and side effects. , 2003, The New England journal of medicine.

[8]  D. Lewis,et al.  57 varieties: the human cytochromes P450. , 2004, Pharmacogenomics.

[9]  Kim L R Brouwer,et al.  Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[10]  D. Lewis,et al.  Human P450s in the metabolism of drugs: molecular modelling of enzyme–substrate interactions , 2005, Expert opinion on drug metabolism & toxicology.

[11]  A. Mrhar,et al.  Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose , 2005, The Pharmacogenomics Journal.

[12]  Ronald W. Davis,et al.  Multiplexed genotyping with sequence-tagged molecular inversion probes , 2003, Nature Biotechnology.

[13]  G. Wilkinson,et al.  Drug metabolism and variability among patients in drug response. , 2005, The New England journal of medicine.

[14]  Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels , 2009 .

[15]  T. Ishizaki,et al.  Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. , 2005, Drug metabolism and pharmacokinetics.

[16]  D Lindhout,et al.  The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. , 1995, The New England journal of medicine.

[17]  M. Relling,et al.  Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. , 1999, Journal of the National Cancer Institute.

[18]  R. Kim,et al.  Molecular basis of ethnic differences in drug disposition and response. , 2001, Annual review of pharmacology and toxicology.

[19]  P. Hardenbol,et al.  Optimal genotype determination in highly multiplexed SNP data , 2006, European Journal of Human Genetics.

[20]  J. Brockmöller,et al.  Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets , 2005, Pharmacogenetics and genomics.

[21]  James Ireland,et al.  Optimal genotype determination in highly multiplexed SNP data , 2006, European Journal of Human Genetics.

[22]  Ncbi National Center for Biotechnology Information , 2008 .

[23]  D. Lipman,et al.  National Center for Biotechnology Information , 2019, Springer Reference Medizin.

[24]  R. Kim Transporters and drug discovery: why, when, and how. , 2006, Molecular pharmaceutics.

[25]  M. Eichelbaum,et al.  Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. , 1991, American journal of human genetics.

[26]  M. Olivier A haplotype map of the human genome , 2003, Nature.

[27]  C. Barthélémy,et al.  An ADHD 6-year-old child ultrarapid metabolizer for CYP2D6. , 2006, Journal of clinical psychopharmacology.

[28]  Shiew-Mei Huang,et al.  Scientific perspectives on drug transporters and their role in drug interactions. , 2006, Molecular pharmaceutics.

[29]  B. Meshkin,et al.  Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications. , 2005, Mutation research.

[30]  R. Weinshilboum Inheritance and drug response. , 2003, The New England journal of medicine.